Publication:
Hidradenitis suppurativa: clinical characteristics and determinants of treatment efficacy

dc.contributor.coauthorGundogdu, Mustafa
dc.contributor.coauthorAkay, Bengu N.
dc.contributor.coauthorBoyvat, Ayse
dc.contributor.coauthorErdem, Cengizhan
dc.contributor.coauthorKocyigit, Pelin
dc.contributor.coauthorBostanci, Seher
dc.contributor.coauthorSanli, Hatice
dc.contributor.coauthorKundakci, Nihal
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorVural, Seçil
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:19:53Z
dc.date.issued2019
dc.description.abstractHidradenitis suppurativa (HS) is a chronic inflammatory skin disorder that causes a significant decline in quality of life. There are numerous treatment options; however, real-life data on the efficacy of these treatments is limited. This study was performed in two centers to describe clinical characteristics and assess treatment outcome in a cohort of 139 patients with HS. Data on demographic and clinical characteristics, Hurley stage and comorbidities were collected from patient charts and evaluated retrospectively. Treatment response was measured with HS clinical response index (HISCR). Mean body mass index was 27.8 +/- 4.88. Inflammatory comorbidities were present in 23%. Among first-line drugs systemic doxycycline resulted in 60% HISCR followed by rifampicin-clindamycin combination (46.4%). Isotretinoin had the lowest HISCR (30.7%) in this group. For second-line therapies, all acitretin treated patients achieved response and patients treated with tumor necrosis factor alpha (TNF-alpha) inhibitors had the highest HISCR. Currently recommended first-line therapies have moderate efficacy in HS. Acitretin appears to be a reasonable alternative for the highly effective TNF-alpha inhibitors in patients with severe and resistant HS. Overall, these results support that excessive inflammatory response play an important role in pathogenesis of HS.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue5
dc.description.openaccessYES
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume32
dc.identifier.doi10.1111/dth.13003
dc.identifier.eissn1529-8019
dc.identifier.issn1396-0296
dc.identifier.scopus2-s2.0-85068734359
dc.identifier.urihttps://doi.org/10.1111/dth.13003
dc.identifier.urihttps://hdl.handle.net/20.500.14288/10629
dc.identifier.wos474893800001
dc.keywordsAcitretin
dc.keywordsdoxycycline
dc.keywordsHidradenitis suppurativa
dc.keywordsHISCR
dc.keywordsInflammation
dc.keywordsInfliximab
dc.keywordsOutcome measure
dc.keywordsRifampicin
dc.keywordsRisk factor
dc.keywordsTreatment
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofDermatologic Therapy
dc.subjectDermatology
dc.titleHidradenitis suppurativa: clinical characteristics and determinants of treatment efficacy
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorVural, Seçil
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files